NERX BIOSCIENCES, INC.

INDIANAPOLIS, IN · Biotech · Private

Small molecule RPA inhibitor (NERx-329) that blocks RPA-DNA interaction to trigger DNA damage response in cancer cells

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · nerxbiosciences.com

Sector: Biotech
Headquarters: INDIANAPOLIS, IN
Latest Form D: $200K, Nov 2021
Total capital: $4.2M

Federal grants: $3.2M; 7 awards · 2015–2025; Rank in peer group#307 of 514
Private capital raised: $1.1M; 2 Form D · last Nov 2021; 60 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Aug 2025Federal grantHealth and Human S · Phase II · Targeting the DNA Damage Response sensor Replication Protein A for first inclass cancer therapy$921K
Aug 2024Federal grantHealth and Human S · Phase II · Targeting the DNA Damage Response sensor Replication Protein A for first inclass cancer therapy$1.1M
Nov 2021Private capital raisedForm D · SEC · 2nd filing$200K
Jan 2019Private capital raisedForm D · SEC · 1st filing$850K
Sep 2017Federal grantHealth and Human S · Phase I · Development of novel Ku targeted kinase inhibitors$300K
Jan 2017Federal grantHealth and Human S · Phase I · A new generation of targeted therapeutics for the treatment of cancer.$50K
Jun 2016Federal grantHealth and Human S · Phase I · Chemical enhancement of CRISPR/Cas9 mediated site-specific genome engineering$293K

Show 2 earlier federal awards

Jun 2015Federal grantHealth and Human S · Phase I · A new generation of targeted therapeutics for the treatment of cancer$299K
May 2015Federal grantHealth and Human S · Phase I · Development of novel lung cancer therapeutics targeting the DNA damage response$249K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

44months

from NERX BIOSCIENCES, INC.’s first federal award to its first private round.

First federal award · May 2015: Health and Human S · $249K
First Form D · Jan 2019: $850K · 1st Form D
Awards before first raise: 5 awards

An association in public records, not a cause or a prediction.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Katherine J. PawelczakResearcherExecutive Officer, DirectorLinked by $3.2M in grants as PI
John J. TurchiExecutive Officer, DirectorNamed in SEC Form D filings
Nicholas J. BallExecutive Officer, DirectorNamed in SEC Form D filings
Trent J. CarrierDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

BIOCOLLECTIVE, LLCSimilar federal contract value in Biotech · null in contracts
Flavocure Biotech, Inc.Similar federal contract value in Biotech · null in contracts
Adolore Biotherapeutics, Inc.Similar federal contract value in Biotech · null in contracts
ThinkBio.Ai, IncSimilar federal contract value in Biotech · null in contracts
BIOKIER, INC.Similar federal contract value in Biotech · null in contracts
Breakaway Labs, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.